SPRED1 and RASopathy: Therefore, despite the modest increase in molecular diagnosis in our study (increased from 23.5% to 25.7% in the validation cohort with an overall positive rate = 3.2% (17/533) for both cohorts), patients with a suspected RASopathy should be tested on an NGS panel that includes the NF1 and SPRED1.